Wynn Capital LLC Takes $1.85 Million Position in Amgen Inc. (NASDAQ:AMGN)

Wynn Capital LLC purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 6,433 shares of the medical research company's stock, valued at approximately $1,853,000. Amgen accounts for about 1.5% of Wynn Capital LLC's investment portfolio, making the stock its 17th biggest position.

Several other hedge funds also recently modified their holdings of AMGN. International Assets Investment Management LLC acquired a new stake in Amgen during the fourth quarter valued at $4,589,900,000. Assenagon Asset Management S.A. boosted its position in Amgen by 486.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 899,232 shares of the medical research company's stock valued at $258,997,000 after purchasing an additional 745,929 shares during the last quarter. abrdn plc boosted its position in Amgen by 150.4% during the fourth quarter. abrdn plc now owns 1,043,609 shares of the medical research company's stock valued at $300,580,000 after purchasing an additional 626,810 shares during the last quarter. Royal Bank of Canada boosted its position in Amgen by 11.4% during the third quarter. Royal Bank of Canada now owns 5,079,677 shares of the medical research company's stock valued at $1,365,213,000 after purchasing an additional 518,689 shares during the last quarter. Finally, California Public Employees Retirement System boosted its position in Amgen by 22.0% during the fourth quarter. California Public Employees Retirement System now owns 2,716,088 shares of the medical research company's stock valued at $782,288,000 after purchasing an additional 490,539 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of AMGN traded down $0.53 on Wednesday, hitting $273.01. The company's stock had a trading volume of 2,466,582 shares, compared to its average volume of 2,840,533. The company has a market capitalization of $146.44 billion, a PE ratio of 21.72, a PEG ratio of 2.53 and a beta of 0.58. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72. The company has a 50 day moving average price of $276.11 and a 200 day moving average price of $281.61.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping the consensus estimate of $4.66 by $0.05. The business had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. Amgen's revenue was up 19.8% compared to the same quarter last year. During the same period in the previous year, the business earned $4.09 EPS. On average, research analysts anticipate that Amgen Inc. will post 19.45 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.30%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen's dividend payout ratio is 72.06%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Royal Bank of Canada restated an "outperform" rating and set a $329.00 target price on shares of Amgen in a report on Wednesday, April 3rd. Leerink Partnrs lowered Amgen from an "outperform" rating to a "market perform" rating in a research note on Wednesday, February 7th. StockNews.com lowered Amgen from a "buy" rating to a "hold" rating in a research note on Thursday, March 28th. SVB Leerink lowered Amgen from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $324.00 to $318.00 in a research note on Wednesday, February 7th. Finally, The Goldman Sachs Group lifted their price objective on Amgen from $313.00 to $350.00 and gave the stock a "buy" rating in a research note on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $296.95.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.